drugset / Trial / NCT02149199

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.

NCT02149199

Phase 3 Completed 3850 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort® 'as needed' will be compared with: 1) terbutaline Turbuhaler® 'as needed' and with 2) Pulmicort (budesonide) Turbuhaler® twice daily plus terbutaline Turbuhaler® 'as needed'.

Timeline

Start
2014-07-07
Primary completion
2017-08-02
Completion
2017-08-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 160 ug Inhaled
Comparator Budesonide Small molecule 200 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled
Comparator Terbutaline Small molecule 0.4 mg Inhaled

Indications